The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a ⁶⁸Ga -DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma on the effect of lan reotide on t umour size.

ABSTRACT:

Introduction

At present, there is no approved medical treatment option for patients with non-functioning pituitary adenoma. A number of open-label studies suggest that treatment with somatostatin analogues may prevent tumour progression. In vivo somatostatin receptor imaging using ⁶⁸Ga-DOTATATE PET (PET, positron emission tomography) could help in preselecting patients potentially responsive to treatment. Our aim is to investigate the effect of the somatostatin analogue lanreotide as compared with placebo on tumour size in patients with a ⁶⁸Ga-DOTATATE PET-positive non-functioning pituitary macroadenoma (NFMA).

Methods and analysis

The GALANT study is a multicentre, randomised, double-blind, placebo-controlled trial in adult patients with a suprasellar

SUBMITTER: Boertien TM 

PROVIDER: S-EPMC7430490 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature